WO2022040644A3 - Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques - Google Patents

Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques Download PDF

Info

Publication number
WO2022040644A3
WO2022040644A3 PCT/US2021/050302 US2021050302W WO2022040644A3 WO 2022040644 A3 WO2022040644 A3 WO 2022040644A3 US 2021050302 W US2021050302 W US 2021050302W WO 2022040644 A3 WO2022040644 A3 WO 2022040644A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
hydroxybutyric acid
oral delivery
gels
suspensions
Prior art date
Application number
PCT/US2021/050302
Other languages
English (en)
Other versions
WO2022040644A2 (fr
Inventor
Gary MILLET
Original Assignee
Axcess Global Sciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/996,509 external-priority patent/US10973786B2/en
Priority claimed from US17/210,646 external-priority patent/US11806324B2/en
Application filed by Axcess Global Sciences, Llc filed Critical Axcess Global Sciences, Llc
Priority to EP21859286.3A priority Critical patent/EP4200274A4/fr
Priority to JP2023512075A priority patent/JP2023541360A/ja
Priority to CN202180070607.5A priority patent/CN116940352A/zh
Priority to MX2023001899A priority patent/MX2023001899A/es
Priority to CA3192343A priority patent/CA3192343A1/fr
Priority to AU2021327408A priority patent/AU2021327408A1/en
Publication of WO2022040644A2 publication Critical patent/WO2022040644A2/fr
Publication of WO2022040644A3 publication Critical patent/WO2022040644A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Les compositions d'acide bêta-hydroxybutyrique destinées à être administrées par voie orale sont sensiblement exemptes de sels de bêta-hydroxybutyrate et sont efficaces pour élever rapidement les taux de cétones dans le sang sans provoquer d'acidose aiguë ou de détresse gastro-intestinale (GI) lorsqu'elles sont consommées sous une forme suffisamment diluée et/ou sous la forme d'un gel ou d'une suspension. Grâce à l'exclusion de sels de bêta-hydroxybutyrate (par exemple, moins de 1 % en poids) contenant des ions de métal alcalin ou alcalino-terreux, les solutions, gels ou suspensions d'acide bêta-hydroxybutyrique peuvent administrer des corps cétoniques exogènes sans modifier de façon significative l'équilibre électrolytique. Bien que les solutions d'acide bêta-hydroxybutyrique aqueuses soient modérément acides avec un pH d'environ 3,5 à 4, lorsque lesdites solutions sont diluées avec une quantité d'eau suffisante, l'eau agit comme un pseudo-tampon qui compense autrement les effets acides sévères lorsque lesdites solutions sont consommées par voie orale. Les gels et les suspensions peuvent également améliorer les effets acides grâce à l'encapsulation partielle de l'acide bêta-hydroxybutyrique. L'acide bêta-hydroxybutyrique peut être enrichi avec l'énantiomère R ou l'énantiomère S, un mélange racémique, de l'acide R-bêta-hydroxybutyrique pur ou de l'acide S-bêta-hydroxybutyrique pur.
PCT/US2021/050302 2020-08-18 2021-09-14 Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques WO2022040644A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP21859286.3A EP4200274A4 (fr) 2020-08-18 2021-09-14 Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques
JP2023512075A JP2023541360A (ja) 2021-03-24 2021-09-14 ベータ－ヒドロキシ酪酸組成物およびケトン体の経口送達方法
CN202180070607.5A CN116940352A (zh) 2021-03-24 2021-09-14 用于经口递送酮体的β-羟基丁酸组合物和方法
MX2023001899A MX2023001899A (es) 2021-03-24 2021-09-14 Composiciones de acido beta-hidroxibutirico y metodos para suministro oral de cuerpos de cetona.
CA3192343A CA3192343A1 (fr) 2020-08-18 2021-09-14 Compositions d'acide beta-hydroxybutyrique et procedes d'administration orale de corps cetoniques
AU2021327408A AU2021327408A1 (en) 2020-08-18 2021-09-14 Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16/996,509 2020-08-18
US16/996,509 US10973786B2 (en) 2016-03-11 2020-08-18 R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US17/210,646 US11806324B2 (en) 2018-04-18 2021-03-24 Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US17/210,646 2021-03-24

Publications (2)

Publication Number Publication Date
WO2022040644A2 WO2022040644A2 (fr) 2022-02-24
WO2022040644A3 true WO2022040644A3 (fr) 2022-04-07

Family

ID=80323202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/050302 WO2022040644A2 (fr) 2020-08-18 2021-09-14 Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques

Country Status (3)

Country Link
EP (1) EP4200274A4 (fr)
AU (1) AU2021327408A1 (fr)
WO (1) WO2022040644A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US20230346699A1 (en) * 2022-04-28 2023-11-02 Axcess Global Sciences, Llc Administration of r-beta-hydroxybutyrate and related compounds in veterinary applications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110287114A1 (en) * 2010-05-24 2011-11-24 Amerilab Technologies, Inc. Effervescent composition for forming a gelled composition, tablet for forming a gelled composition, and method of making a gelled composition
WO2018187324A1 (fr) * 2017-04-04 2018-10-11 NNB Nutrition USA, LLC Préparation de l'acide (r)-3-hydroxybutyrique ou ses sels par fermentation en une étape
US20190177673A1 (en) * 2017-08-23 2019-06-13 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
WO2019204148A1 (fr) * 2018-04-18 2019-10-24 Access Global Sciences, Llc Compositions et procédés pour l'empilement céto avec du bêta-hydroxybutyrate et de l'acétoacétate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5030553B2 (ja) * 2006-11-24 2012-09-19 有限会社ノーベル医学研究所 ドライマウスおよび／または唾液分泌障害を処置するための医薬
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
GB201616058D0 (en) * 2016-09-21 2016-11-02 Chain Biotechnology Ltd Probiotic composition
JP6804352B2 (ja) * 2017-03-22 2020-12-23 大阪瓦斯株式会社 コラゲナーゼｍｍｐ１及び３の産生抑制剤
US11806324B2 (en) * 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
CA3022995C (fr) * 2018-06-12 2019-10-15 Ketofibe (9211-3133 Quebec Inc.) Composes cetogenes novateurs, compositions, methodes et utilisations associees
CA3170624A1 (fr) * 2020-03-05 2021-09-10 VitaNav, Inc. Composition d'acide (d)-?-hydroxybutyrique, d'acide (d)-?-hydroxyvalerique et de (d)-1,3 butanediol en tant que supplement nutritionnel et agent therapeutique
CN112262936A (zh) * 2020-10-22 2021-01-26 珠海麦得发生物科技股份有限公司 一种含3-羟基丁酸的饮品及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110287114A1 (en) * 2010-05-24 2011-11-24 Amerilab Technologies, Inc. Effervescent composition for forming a gelled composition, tablet for forming a gelled composition, and method of making a gelled composition
WO2018187324A1 (fr) * 2017-04-04 2018-10-11 NNB Nutrition USA, LLC Préparation de l'acide (r)-3-hydroxybutyrique ou ses sels par fermentation en une étape
US20190177673A1 (en) * 2017-08-23 2019-06-13 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
WO2019204148A1 (fr) * 2018-04-18 2019-10-24 Access Global Sciences, Llc Compositions et procédés pour l'empilement céto avec du bêta-hydroxybutyrate et de l'acétoacétate

Also Published As

Publication number Publication date
EP4200274A2 (fr) 2023-06-28
AU2021327408A1 (en) 2023-04-20
EP4200274A4 (fr) 2024-10-23
WO2022040644A2 (fr) 2022-02-24

Similar Documents

Publication Publication Date Title
WO2022040644A3 (fr) Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques
RU2009146297A (ru) Дезинфекционное средство на основе водных растворов, которые содержат хлорноватистую кислоту (hocl), способ его получения и применение
JP5757975B2 (ja) 二酸化塩素用の安定化組成物
CA2555136A1 (fr) Compositions d'absorption d'oxygene et procede correspondant
US8951576B2 (en) Process for producing aqueous chlorous acid solution for use as disinfectant
TWI737981B (zh) 使用醣類之益生元口腔保健方法
RU2011152950A (ru) Композиция зубной пасты
RU2011109191A (ru) Противомикробные растворы серебра
EP2554050A4 (fr) Agent à base de chlore combiné, et son procédé de fabrication et son procédé d'utilisation
RU2012150279A (ru) Гранулы фермента
JP2013151409A5 (fr)
NZ599377A (en) Salts, aqueous liquid compositions containing salts of S-(+)-abscisic acid and methods of their preparation
BR112014015935A8 (pt) composição de agentes de detecção de células tumorais epiteliais e seu método de preparação
RU2015121111A (ru) Композиция по уходу за полостью рта
MX2023001899A (es) Composiciones de acido beta-hidroxibutirico y metodos para suministro oral de cuerpos de cetona.
RU2012113844A (ru) Пероральные суспензионные лекарственные формы ацетата эсликарбазепина
PH12016500909B1 (en) Solutons for increasing the stability and shelf life of an organ tissue preservation solution
PL375919A1 (en) Coated peroxygen compounds with controlled release, a process for their preparation and their use
RU2011111321A (ru) Композиция зубной пасты
DK168529B1 (da) Mundplejemiddel og fremgangsmåde til fremstilling deraf
MX2009012161A (es) Formulaciones de dentífrico que contienen peróxidos estables al color con nanopartículas de envolvente de sílice encapsuladas con colorante.
CA2797069A1 (fr) Particule
RU2008111067A (ru) Стабилизированные и консервированные глазные композиции, содержащие кетотифен
JP2014073451A5 (fr)
TR201006273T1 (tr) Fotosentezi hızlandıracak bir ürün.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21859286

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2023512075

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3192343

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021859286

Country of ref document: EP

Effective date: 20230320

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21859286

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202180070607.5

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2021327408

Country of ref document: AU

Date of ref document: 20210914

Kind code of ref document: A